A single dose of the short-acting NMDA antagonist ketamine produces rapid and prolonged
antidepressant effects in treatment-resistant patients with major depressive disorder (MDD) …

Currently available medications have significant limitations, most notably low response rate
and time lag for treatment response. Recent clinical studies have demonstrated that …

In the search for new drug targets, that may help point the way to develop fast-acting
treatments for mood disorders, we have explored molecular pathways regulated by …

The N-methyl-d-aspartate (NMDA) receptor antagonist ketamine has rapid and potent
antidepressant effects in treatment-resistant major depressive disorder and bipolar …

A debilitating mental disorder, major depressive disorder is a leading cause of global
disease burden. Existing antidepressant drugs are not adequate for the majority of …

Recent reports of a rapid antidepressant effect of the glutamate N‐methyl‐d‐aspartate
(NMDA) receptor antagonist ketamine, even in treatment‐resistant populations, have …

A single, low dose of ketamine evokes antidepressant actions in depressed patients and in
patients with treatment-resistant depression (TRD). Unlike classic antidepressants, which …

Background Clinical studies demonstrate that the N-methyl-D-aspartate (NMDA) receptor
antagonist, ketamine, induces rapid antidepressant effects in patients with refractive major …

Highlights•Ketamine triggers a rapid antidepressant response in patients with major
depression.•Ketamine elicits rapid translation of brain-derived neurotrophic factor …

Major depressive disorder (MDD) is a common and debilitating psychiatric disorder.
Traditional antidepressants are of limited efficacy and take weeks to months to yield full …